Industries > Pharma > Antibody Production Market Report to 2031
Antibody Production Market Report to 2031
By Process, The Market Is Categorized As (Upstream Processing (Bioreactors, Consumables), Downstream Processing (Chromatography Systems, Chromatography Resins), Filtration (Filtration Systems, Filtration Consumables & Accessories), By Type (Monoclonal, Polyclonal), By End User (Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories, Others)
Antibody Production Market– our new study reveals trends, R&D progress, and predicted revenues
Where is the Antibody Production Market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities, and business prospects there.
Discover how to stay ahead
Our Antibody Production report provides tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Antibody Production Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), product profiles and commercial developments.
Antibody Production Market by Process
• Upstream Processing
o Bioreactors
– Large-scale Bioreactors
– Single-use Bioreactors
• Consumables
o Media
o Buffers & Reagents
• Downstream Processing
o Chromatography Systems
o Chromatography Resins
• Filtration
o Filtration Systems
o Filtration Consumables & Accessories
Antibody Production Market by Type
• Monoclonal
• Polyclonal
Antibody Production Market by End User
• Pharmaceutical & Biotechnology Companies
• Diagnostic Laboratories
• Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Japan
o Rest of Asia Pacific
• Latin America
o Rest of Latin America
• Middle East and Africa
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Antibody Production Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Antibody Production Market with forecasts for by process, by type and by end user each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Antibody Production Market report helps you
In summary, our 280+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Antibody Production Market, with forecasts for by process, By type, and By end user each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 20 key national markets – See forecasts for the Antibody Production Market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, Rest of Asia Pacific, Latin America and Middle East and Africa among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for Antibody Production of the major companies involved in the Antibody Production Market. Some of the company’s profiled in this report include-
• GE Healthcare
• Thermo Fisher Scientific, Inc.
• 3M
• Abcam PLC
• GeneTex, Inc.
• Sartorius AG
• Merck KGaA
• Pall Corporation
• Sigma-Aldrich Corporation
• Eppendorf AG
• Cellab GmbH
• Pfizer Inc.
• INTEGRA Biosciences AG
• FiberCell Systems Inc.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
With Information found nowhere else
our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.
Visiongain’s study is for everybody needing commercial analyses for the global Antibody Production Market and leading companies. You will find data, trends, and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Antibody Production Market Report to 2031: By Process, The Market Is Categorized As (Upstream Processing (Bioreactors, Consumables), Downstream Processing (Chromatography Systems, Chromatography Resins), Filtration (Filtration Systems, Filtration Consumables & Accessories), By Type (Monoclonal, Polyclonal), By End User (Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories, Others). Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Global Antibody Production Market
2.1. Antibody Production Market Definition
2.2. By Process Submarkets Definitions
2.3. By Type Submarkets Definitions
2.4. By End User Submarkets Definitions
3. Antibody Production Market Overview
3.1. Global Antibody Production Market Size and Forecast by Region
3.2. Global Antibody Production Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Rising adoption of targeted immunotherapy
3.3.1.2. Increasing R&D activities in pharmaceutical and biotechnological Companies
3.3.2. Market Restraints/Challenges
3.3.2.1. High cost involved in R&D.
3.3.2.2. Stringent government regulations
3.3.3. Opportunities
3.3.3.1. Increasing demand for Protein Therapeutics
3.3.3.2. Rising prevalence of Infectious Diseases
3.3.3.3. Expiring patent of therapeutic monoclonal antibody.
3.3.4. Porter’s Five Forces Analysis
3.3.4.1. Competitive Rivalry
3.3.4.2. Supplier Power
3.3.4.3. Buyer Power
3.3.4.4. Threat of Substitution
3.3.4.5. Threat of New Entry
4. Global Antibody Production Market Analysis and Forecast 2021-2031, By Process (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Upstream Processing
4.1.2. Raised from host cells and used for manufacturing to bioreactors type and capacity.
4.1.2.1. Bioreactors
4.1.2.1.1. Large-scale Bioreactors
4.1.2.1.2. Single-use Bioreactors
4.1.2.2. Consumables
4.1.2.2.1. Media
4.1.2.2.2. Buffers & Reagents
4.2. Downstream Processing
4.2.1. Chromatography-based separations involve high cost of large-scale production.
4.2.2. Chromatography Systems
4.2.3. Chromatography Resins
4.3. Filtration
4.3.1. The media filtration enables to prevent unwanted contaminants caused by bacteria and viruses
4.3.2. Filtration Systems
4.3.3. Filtration Consumables & Accessories
5. Global Antibody Production Market Analysis and Forecast, 2021-2031 by type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Monoclonal
5.1.2. The primary method of monoclonal antibody production involves using murine systems to produce antibodies to specific human) antigens.
5.1.3. Polyclonal
5.1.4. Antigen purified through heterogeneous collection of antigen-binding Immunoglobulins.
6. Global Antibody Production Market Analysis and Forecast, 2021-2031 by End User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Pharmaceutical & Biotechnology Companies
6.1.2. Involved in investment for R&D of antibody.
6.1.3. Diagnostic Laboratories
6.1.4. Antibody is considered as the powerful tool for diagnostic purpose.
6.1.5. Others
7. North America Antibody Production Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. North America Antibody Production Market Size and Forecast By Process
7.3. North America Antibody Production Market Size and Forecast By Type
7.4. North America Antibody Production Market Size and Forecast by End User
7.5. U.S. Antibody Production Market
7.5.1. Increasing initiative for R&D on antibody from biotechnological companies.
7.6. Canada Antibody Production Market
7.6.1. Government of Canada under Innovation, Science and Economic Development’s (ISED) Strategic Innovation Fund (SIF) to expand discovery of antibodies.
8. Europe Antibody Production Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Europe Antibody Production Market Size and Forecast By Process
8.3. Europe Antibody Production Market Size and Forecast By Type
8.4. Europe Antibody Production Market Size and Forecast by End User
8.5. UK Antibody Production Market
8.5.1. Increasing demand of antibody for therapeutic purpose.
8.6. Germany Antibody Production Market
8.6.1. Germany to organize antibody test program
8.7. France Antibody Production Market
8.7.1. Increasing investment for R&D in the region.
8.8. Rest of Europe Antibody Production Market
9. Asia Pacific Antibody Production Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Asia Pacific Antibody Production Market Size and Forecast By Process
9.3. Asia Pacific Antibody Production Market Size and Forecast By Type
9.4. Asia Pacific Antibody Production Market Size and Forecast by End User
9.5. China Antibody Production Market
9.5.1. Increasing production of antibody in the region.
9.6. India Antibody Production Market
9.6.1. Rising demand for cost effective therapeutic treatments in the region.
9.7. Japan Antibody Production Market
9.7.1. Increasing antibody production in the region.
9.8. Rest of Asia Pacific Antibody Production Market
10. Latin America Antibody Production Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Latin America Antibody Production Market Size and Forecast By Process
10.3. Latin America Antibody Production Market Size and Forecast By Type
10.4. Latin America Antibody Production Market Size and Forecast By End User
10.4.1. Brazil Antibody Production Market
10.4.1.1. Increasingly risk for acute respiratory infections.
10.4.2. Mexico Antibody Production Market
10.4.2.1. Prevalence of infectious diseases.
10.4.3. Rest of Latin America Antibody Production Market
11. MEA Antibody Production Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. MEA Antibody Production Market Size and Forecast By Process
11.3. MEA Antibody Production Market Size and Forecast By Type
11.4. MEA Antibody Production Market Size and Forecast By End User
11.5. South Africa Antibody Production Market
11.5.1.1. High incidence of mortality due to infectious diseases
11.6. Rest of MEA Antibody Production Market
12. Companies in the Antibody Production Market
12.1. GE Healthcare
12.1.1. Company Snapshot
12.1.2. Company Overview
12.1.3. Financial Performance (2015-2020)
12.1.3.1. Net Revenue
12.1.3.2. Gross Profit
12.1.3.3. Geographical Revenue, 2020
12.1.4. Product Offerings
12.1.5. Recent Initiatives (2017-2020)
12.2. Thermo Fisher Scientific, Inc.
12.2.1. Company Snapshot
12.2.2. Company Overview
12.2.3. Financial Performance (2015-2020)
12.2.3.1. Net Revenue
12.2.3.2. Gross Profit
12.2.3.3. Geographical Revenue, 2020
12.2.4. Product Offerings
12.2.5. Recent Initiatives (2017-2020)
12.3. 3M
12.3.1. Company Snapshot
12.3.2. Company Overview
12.3.3. Financial Performance (2015-2020)
12.3.3.1. Net Revenue
12.3.3.2. Gross Profit
12.3.3.3. Geographical Revenue, 2020
12.3.4. Product Offerings
12.3.5. Recent Initiatives (2017-2020)
12.4. Abcam PLC
12.4.1. Company Snapshot
12.4.2. Company Overview
12.4.3. Financial Performance (2015-2020)
12.4.3.1. Net Revenue
12.4.3.2. Gross Profit
12.4.3.3. Geographical Revenue, 2020
12.4.4. Product Offerings
12.4.5. Recent Initiatives (2017-2020)
12.5. GeneTex, Inc.
12.5.1. Company Snapshot
12.5.2. Company Overview
12.5.3. Financial Performance (2015-2020)
12.5.3.1. Net Revenue
12.5.3.2. Gross Profit
12.5.3.3. Geographical Revenue, 2020
12.5.4. Product Offerings
12.5.5. Recent Initiatives (2017-2020)
12.6. Sartorius AG
12.6.1. Company Snapshot
12.6.2. Company Overview
12.6.3. Financial Performance (2015-2020)
12.6.3.1. Net Revenue
12.6.3.2. Gross Profit
12.6.3.3. Geographical Revenue, 2020
12.6.4. Product Offerings
12.6.5. Recent Initiatives (2017-2020)
12.7. Merck KGaA
12.7.1. Company Snapshot
12.7.2. Company Overview
12.7.3. Financial Performance (2015-2020)
12.7.3.1. Net Revenue
12.7.3.2. Gross Profit
12.7.3.3. Geographical Revenue, 2020
12.7.4. Product Offerings
12.7.5. Recent Initiatives (2017-2020)
12.8. Pall Corporation
12.8.1. Company Snapshot
12.8.2. Company Overview
12.8.3. Financial Performance (2015-2020)
12.8.3.1. Net Revenue
12.8.3.2. Gross Profit
12.8.3.3. Geographical Revenue, 2020
12.8.4. Product Offerings
12.8.5. Recent Initiatives (2017-2020)
12.9. Sigma-Aldrich Corporation
12.9.1. Company Snapshot
12.9.2. Company Overview
12.9.3. Financial Performance (2015-2020)
12.9.3.1. Net Revenue
12.9.3.2. Gross Profit
12.9.3.3. Geographical Revenue, 2020
12.9.4. Product Offerings
12.9.5. Recent Initiatives (2017-2020)
12.10. Eppendorf AG
12.10.1. Company Snapshot
12.10.2. Company Overview
12.10.3. Financial Performance (2015-2020)
12.10.3.1. Net Revenue
12.10.3.2. Gross Profit
12.10.3.3. Geographical Revenue, 2020
12.10.4. Product Offerings
12.10.5. Recent Initiatives (2017-2020)
12.11. Other Notable Players
13. Conclusion
14. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Antibody Production Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Antibody Production Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Antibody Production Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Antibody Production Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Antibody Production Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Antibody Production Market Drivers & Restraints 2021
Table 7. Antibody Production Submarket Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Antibody Production Submarket Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Antibody Production Submarket Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Antibody Production Submarket Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Antibody Production Submarket Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Upstream Processing Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Upstream Processing Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Upstream Processing Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Upstream Processing Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Upstream Processing Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Downstream Processing Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Downstream Processing Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Downstream Processing Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Downstream Processing Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Downstream Processing Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Filtration Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Filtration Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Filtration Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Filtration Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Filtration Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Antibody Production Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 28. Antibody Production Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Antibody Production Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Antibody Production Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Antibody Production Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Monoclonal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Monoclonal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Monoclonal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Monoclonal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Monoclonal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Polyclonal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Polyclonal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Polyclonal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Polyclonal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Polyclonal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Antibody Production Market Forecast by End User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Antibody Production Market Forecast by End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Antibody Production Market Forecast by End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Antibody Production Market Forecast by End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Antibody Production Market Forecast by End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Pharmaceutical & Biotechnology Companies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Pharmaceutical & Biotechnology Companies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Pharmaceutical & Biotechnology Companies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Pharmaceutical & Biotechnology Companies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Pharmaceutical & Biotechnology Companies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Diagnostic Laboratories Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table53. Diagnostic Laboratories Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Diagnostic Laboratories Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Diagnostic Laboratories Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Diagnostic Laboratories Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Regional Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 58. Regional Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Regional Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Regional Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Regional Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 62. North America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 63. North America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 64. North America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 65. North America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 66. North America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 67. North America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 68. North America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 69. North America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 70. North America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 71. North America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 72. North America Antibody Production Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 73. North America Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 74. North America Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 75. North America Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table76. North America Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 77. North America Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 78. North America Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 79. North America Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 80. North America Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 81. North America Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 82. US Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 83. US Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 84. US Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 85. US Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 86. US Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Canada Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 88. Canada Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Canada Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Canada Antibody Production Market Forecast 2021-2031 (US$M, AGR % CAGR %) (COVID - Scenario W)
Table 91. Canada Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Europe Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 93. Europe Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Europe Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Europe Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Europe Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Europe Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 98. Europe Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Europe Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Europe Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Europe Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Europe Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 103. Europe Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Europe Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Europe Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Europe Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Europe Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 108. Europe Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Europe Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Europe Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Europe Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 112. UK Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 113. UK Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 114. UK Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 115. UK Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 116. UK Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Germany Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 118. Germany Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Germany Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Germany Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Germany Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 122. France Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 123. France Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 124. France Antibody Production Market Forecast 2021-2031 (US$M, AGR % CAGR %) (COVID - Scenario U)
Table 125. France Antibody Production Market Forecast 2021-2031 (US$M, AGR % CAGR %), (COVID - Scenario W)
Table 126. France Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Rest of Europe Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 128. Rest of Europe Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Rest of Europe Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Rest of Europe Antibody Production Market Forecast 2021-2031 (US$M, AGR%, CAGR %) (COVID - Scenario W)
Table 131. Rest of Europe Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Asia Pacific Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 133. Asia Pacific Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Asia Pacific Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Asia Pacific Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Asia Pacific Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Asia Pacific Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 138. Asia Pacific Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Asia Pacific Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Asia Pacific Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Asia Pacific Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 142. Asia Pacific Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 143. Asia Pacific Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 144. Asia Pacific Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 145. Asia Pacific Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 146. Asia Pacific Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L
Table 147. Asia Pacific Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 148. Asia Pacific Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Asia Pacific Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Asia Pacific Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Asia Pacific Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 152. China Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153. China Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154. China Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 155. China Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 156. China Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157. India Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158. India Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159. India Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. India Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161. India Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Japan Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. Japan Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Japan Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Japan Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Japan Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167. RoAPAC Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168. RoAPAC Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. RoAPAC Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170. RoAPAC Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. RoAPAC Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Middle East Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173. Middle East Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. Middle East Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175 Middle East Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. Middle East Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177. Middle East Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. Middle East Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. Middle East Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. Middle East Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. Middle East Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182 Middle East Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183 Middle East Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. Middle East Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185. Middle East Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. Middle East Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. Latin America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. Latin America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. Latin America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190. Latin America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table191. Latin America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192. Latin America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table193. Latin America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. Latin America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. Latin America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. Latin America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. Latin America Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198. Latin America Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199 Latin America Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. Latin America Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. Latin America Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202 Leading 10 Antibody Production Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 203. GE Healthcare Profile 2021 (CEO, HQ, Founded, Website)
Table 253. GE Healthcare Antibody Production Selected Recent Contracts 2021 (Date, Programme Type, Details)
Table 204. GE Healthcare Antibody Production Product Offering (Segment, Product Offerings)
Table 205. Thermo Fisher Scientific, Inc. Profile 2021 (CEO, HQ, Founded, Website)
Table 206. Thermo Fisher Scientific, Inc. Antibody Production Product Offering (Segment, Product Offerings)
Table 207. 3M Profile 2021 (CEO, HQ, Founded, Website)
Table 208. 3M Antibody Production Selected Recent Contracts 2017-2020 (Date, Programme Type, Details)
Table 209. 3M Antibody Production Product Offering (Segment, Product Offerings)
Table 210. Abcam PLC Profile 2021 (CEO, HQ, Founded, Website)
Table 211. Abcam PLC Selected Recent Contracts 2015-2021 (Date, Programme Type, Details)
Table 212. Abcam PLC Antibody Production Parasiticides Product Offering (Segment, Product Offerings)
Table 213. GeneTex, Inc. Profile 2021 (CEO, HQ, Founded, Website)
Table 214. GeneTex, Inc. Antibody Production Product Offering (Segment, Product Offerings)
Table 215. Sartorius AG Profile 2021 (CEO, HQ, Founded, Website)
Table 216. Sartorius AG Antibody Production Selected Recent Contracts 2015-2021 (Date, Programme Type, Details)
Table 217 Sartorius AG Antibody Production Product Offering (Segment, Product Offerings)
Table 218. Merck KGaA Profile 2021 (CEO, HQ, Founded, Website)
Table 219. Merck KGaA Antibody Production Product Offering (Segment, Product Offerings)
Table 220. Pall Corporation, Profile 2021 (CEO, HQ, Founded, Website)
Table 221. Pall Corporation, Antibody Production Product Offering (Segment, Product Offerings)
Table 222. Sigma-Aldrich Corporation Profile 2021 (CEO, HQ, Founded, Website)
Table 223. Sigma-Aldrich Corporation Antibody Production Product Offering (Segment, Product Offerings)
Table 224. Eppendorf AG Profile 2021 (CEO, Total Company Sales US$M, HQ, Founded, No. of Employees, Ticker, Website)
Table 225. Eppendorf AG Total Company Sales 2015-2021 (US$M, AGR %)
Table 226. Eppendorf AG Product Offering (Segment, Product Offerings)
Table 227. Other Companies Involved in the Antibody Production Market (Company, Location)
LIST OF FIGURES
Figure 1. Antibody Production Market Type Overview
Figure 2. Antibody Production Market By Process Overview
Figure 3. Antibody Production Market By Type Overview
Figure 4. Antibody Production Market End User Overview
Figure 5. Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 6. Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 7. Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 8. Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 9. Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 10. Antibody Production Submarket Forecast By Process 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 11. Antibody Production Submarket Forecast By Process 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 12. Antibody Production Submarket Forecast By Process 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 13. Antibody Production Submarket Forecast By Process 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 14. Antibody Production Submarket Forecast By Process 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 15. Antibody Production Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 16. Antibody Production Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 17. Antibody Production Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 18. Antibody Production Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 19. Antibody Production Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 20. Antibody Production Submarket Forecast by End User 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 21. Antibody Production Submarket Forecast by End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 22. Antibody Production Submarket Forecast by End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 23. Antibody Production Submarket Forecast by End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 24. Antibody Production Submarket Forecast by End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 25. Regional Antibody Production Market Forecast 2021-2031 (Sales US$M, Global AGR %) (Before COVID)
Figure 26. Regional Antibody Production Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario V)
Figure27. Regional Antibody Production Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario U)
Figure 28. Regional Antibody Production Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario W)
Figure 29. Regional Antibody Production Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario L)
Figure 30. North America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %) (Before COVID)
Figure 31. North America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 32. North America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 33. North America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 34. North America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 35. North America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %) (Before COVID)
Figure 36. North America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 37. North America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 38. North America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 39. North America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 40. North America Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %) (Before COVID)
Figure 41. North America Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 42. North America Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 43. North America Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 44. North America Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 45. North America Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 46. North America Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 47. North America Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 48. North America Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 49. North America Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 50. US Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 51. US Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 52. US Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 53. US Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 54. US Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 55. Canada Antibody Production Market Forecast 2021-2031 (US$M, AGR %)
Figure 56. Canada Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 57. Canada Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 58. Canada Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 59. Canada Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 60. Europe Antibody Production Market Forecast By Process 2021-2031 (US$M)
Figure 61. Europe Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario V)
Figure 62. Europe Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario U)
Figure 63. Europe Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario W)
Figure 64. Europe Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario L)
Figure 65. Europe Antibody Production Market Forecast By Type 2021-2031 (US$M) (Before COVID)
Figure 66. Europe Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 67. Europe Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 68. Europe Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 69. Europe Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 70. Europe Antibody Production Market Forecast by End User 2021-2031 (US$M) (Before COVID)
Figure 71. Europe Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 72. Europe Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 73. Europe Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 74. Europe Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 75. Europe Antibody Production Market Forecast by Country 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 76. Europe Antibody Production Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 77. Europe Antibody Production Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 78. Europe Antibody Production Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 79. Europe Antibody Production Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 80. UK Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 81. UK Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 82. UK Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID – Scenario U)
Figure 83. UK Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 84. UK Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 85. Germany Antibody Production Market Forecast 2021-2031 (US$M, AGR %)
Figure 86. Germany Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 87. Germany Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 88. Germany Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 89. Germany Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 90. France Antibody Production Market Forecast 2021-2031 (US$M, AGR %)
Figure 91. France Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 92. France Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 93. France Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 94. France Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 95. Rest of Europe Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 96. Rest of Europe Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 97. Rest of Europe Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 98. Rest of Europe Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 99. Rest of Europe Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 100 Asia-Pacific Antibody Production Market Forecast By Process 2021-2031 (US$M) (Before COVID)
Figure 101. Asia-Pacific Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario V)
Figure 102. Asia-Pacific Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario U)
Figure 103. Asia-Pacific Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario W)
Figure 104. Asia-Pacific Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario L)
Figure 105. Asia-Pacific Antibody Production Market Forecast By Type 2021-2031 (US$M)
Figure 106. Asia-Pacific Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 107. Asia-Pacific Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 108. Asia-Pacific Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 109. Asia-Pacific Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 110. Asia-Pacific Antibody Production Market Forecast By Type 2021-2031 (US$M)
Figure 111. Asia-Pacific Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 112. Asia-Pacific Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 113. Asia-Pacific Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 114. Asia-Pacific Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 115. Asia-Pacific Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 116. Asia-Pacific Antibody Production Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 117. Asia-Pacific Antibody Production Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 118. Asia-Pacific Antibody Production Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 119. Asia-Pacific Antibody Production Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 120. China Antibody Production Market Forecast 2021-2031 (US$M, AGR %)
Figure 121. China Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 122. China Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 123 China Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 124. China Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 125. India Antibody Production Market Forecast 2021-2031 (US$M, AGR %)
Figure 126. India Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 127. India Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 128. India Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 129. India Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 130. Japan Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 131. Japan Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 132. Japan Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 133. Japan Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 134. Japan Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 135. Rest of APAC Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 136. Rest of APAC Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 137 Rest of APAC Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 138. Rest of APAC Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 139. Rest of APAC Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 140. Middle East Antibody Production Market Forecast By Process 2021-2031 (US$M)
Figure 141. Middle East Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario V)
Figure 142. Middle East Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario U)
Figure 143. Middle East Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario W)
Figure 144. Middle East Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario L)
Figure 145. Middle East Antibody Production Market Forecast By Type 2021-2031 (US$M)
Figure 146. Middle East Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 147 Middle East Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 148. Middle East Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 149. Middle East Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 150. Middle East Antibody Production Market Forecast by End User 2021-2031 (US$M)
Figure 151. Middle East Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 152. Middle East Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 153. Middle East Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 154. Middle East Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 155. Rest of Middle East Antibody Production Market Forecast 2021-2031 (US$M, AGR %)
Figure 156. Rest of Middle East Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 157. Rest of Middle East Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 158. Rest of Middle East Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 159. Rest of Middle East Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 160. Latin America Antibody Production Market Forecast By Process 2021-2031 (US$M)
Figure 161. Latin America Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario V)
Figure 162. Latin America Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario U)
Figure 163. Latin America Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario W)
Figure 164. Latin America Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario L)
Figure 165. Latin America Antibody Production Market Forecast By Type 2021-2031 (US$M)
Figure 166. Latin America Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 167. Latin America Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 168. Latin America Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 169. Latin America Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 170. Latin America Antibody Production Market Forecast by End User 2021-2031 (US$M)
Figure 171. Latin America Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 172. Latin America Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 173. Latin America Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 174. Latin America Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 175. Rest of Latin America Antibody Production Market Forecast 2021-2031 (US$M, AGR %)
Figure 176. Rest of Latin America Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 177. Rest of Latin America Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 178. Rest of Latin America Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 179. Rest of Latin America Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 180. Porter’s Five Force Analysis
Companies Mentioned
1. GE Healthcare
2. Thermo Fisher Scientific, Inc.
3. 3M
4. Abcam PLC
5. GeneTex, Inc.
6. Sartorius AG
7. Merck KGaA
8. Pall Corporation
9. Sigma-Aldrich Corporation
10. Eppendorf AG
11. Cellab GmbH
12. Pfizer
13. INTEGRA Biosciences AG
14. FiberCell Systems Inc.
15. Eli Lilly and Company
16. Abcam PLC
17. Alexion
18. F. Hoffmann-La Roche AG
19. Janssen Biologics
20. AbbVie
21. Novartis AG
22. Gilead Sciences
23. AstraZeneca
24. Glenmark Pharmaceuticals Ltd.
25. CytoDyn Inc.
26. Regeneron Pharmaceuticals, Inc.
27. Immunic Inc.
28. Molecular Partners AG
29. Biophytis SA
30. HiFiBiO Inc.
31. Atea Pharmaceuticals, Inc.
32. UNION therapeutics A/S
33. Appili Therapeutics Inc.
34. GlaxoSmithKline Biologicals
35. Corvus Pharmaceuticals Inc.
36. Sorrento Therapeutics, Inc.
37. Eiger BioPharmaceuticals, Inc.
38. Amgen Inc.
39. Vir Biotechnology
40. Humanigen Inc.
41. Innovation pharmaceuticals Inc.
42. Mateon Therapeutics
43. Dr. Reddy’s Laboratories Ltd.
44. RedHill Biopharma Ltd
45. Harbour BioMed
46. Mesoblast Limited
47. Organicell Regenerative Medicine, Inc.
48. Abeome Corporation
49. Laurent Pharmaceuticals Inc
50. Capricor Therapeutic
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Global Antibody Production Market
2.1. Antibody Production Market Definition
2.2. By Process Submarkets Definitions
2.3. By Type Submarkets Definitions
2.4. By End User Submarkets Definitions
3. Antibody Production Market Overview
3.1. Global Antibody Production Market Size and Forecast by Region
3.2. Global Antibody Production Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Rising adoption of targeted immunotherapy
3.3.1.2. Increasing R&D activities in pharmaceutical and biotechnological Companies
3.3.2. Market Restraints/Challenges
3.3.2.1. High cost involved in R&D.
3.3.2.2. Stringent government regulations
3.3.3. Opportunities
3.3.3.1. Increasing demand for Protein Therapeutics
3.3.3.2. Rising prevalence of Infectious Diseases
3.3.3.3. Expiring patent of therapeutic monoclonal antibody.
3.3.4. Porter’s Five Forces Analysis
3.3.4.1. Competitive Rivalry
3.3.4.2. Supplier Power
3.3.4.3. Buyer Power
3.3.4.4. Threat of Substitution
3.3.4.5. Threat of New Entry
4. Global Antibody Production Market Analysis and Forecast 2021-2031, By Process (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Upstream Processing
4.1.2. Raised from host cells and used for manufacturing to bioreactors type and capacity.
4.1.2.1. Bioreactors
4.1.2.1.1. Large-scale Bioreactors
4.1.2.1.2. Single-use Bioreactors
4.1.2.2. Consumables
4.1.2.2.1. Media
4.1.2.2.2. Buffers & Reagents
4.2. Downstream Processing
4.2.1. Chromatography-based separations involve high cost of large-scale production.
4.2.2. Chromatography Systems
4.2.3. Chromatography Resins
4.3. Filtration
4.3.1. The media filtration enables to prevent unwanted contaminants caused by bacteria and viruses
4.3.2. Filtration Systems
4.3.3. Filtration Consumables & Accessories
5. Global Antibody Production Market Analysis and Forecast, 2021-2031 by type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Monoclonal
5.1.2. The primary method of monoclonal antibody production involves using murine systems to produce antibodies to specific human) antigens.
5.1.3. Polyclonal
5.1.4. Antigen purified through heterogeneous collection of antigen-binding Immunoglobulins.
6. Global Antibody Production Market Analysis and Forecast, 2021-2031 by End User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Pharmaceutical & Biotechnology Companies
6.1.2. Involved in investment for R&D of antibody.
6.1.3. Diagnostic Laboratories
6.1.4. Antibody is considered as the powerful tool for diagnostic purpose.
6.1.5. Others
7. North America Antibody Production Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. North America Antibody Production Market Size and Forecast By Process
7.3. North America Antibody Production Market Size and Forecast By Type
7.4. North America Antibody Production Market Size and Forecast by End User
7.5. U.S. Antibody Production Market
7.5.1. Increasing initiative for R&D on antibody from biotechnological companies.
7.6. Canada Antibody Production Market
7.6.1. Government of Canada under Innovation, Science and Economic Development’s (ISED) Strategic Innovation Fund (SIF) to expand discovery of antibodies.
8. Europe Antibody Production Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Europe Antibody Production Market Size and Forecast By Process
8.3. Europe Antibody Production Market Size and Forecast By Type
8.4. Europe Antibody Production Market Size and Forecast by End User
8.5. UK Antibody Production Market
8.5.1. Increasing demand of antibody for therapeutic purpose.
8.6. Germany Antibody Production Market
8.6.1. Germany to organize antibody test program
8.7. France Antibody Production Market
8.7.1. Increasing investment for R&D in the region.
8.8. Rest of Europe Antibody Production Market
9. Asia Pacific Antibody Production Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Asia Pacific Antibody Production Market Size and Forecast By Process
9.3. Asia Pacific Antibody Production Market Size and Forecast By Type
9.4. Asia Pacific Antibody Production Market Size and Forecast by End User
9.5. China Antibody Production Market
9.5.1. Increasing production of antibody in the region.
9.6. India Antibody Production Market
9.6.1. Rising demand for cost effective therapeutic treatments in the region.
9.7. Japan Antibody Production Market
9.7.1. Increasing antibody production in the region.
9.8. Rest of Asia Pacific Antibody Production Market
10. Latin America Antibody Production Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Latin America Antibody Production Market Size and Forecast By Process
10.3. Latin America Antibody Production Market Size and Forecast By Type
10.4. Latin America Antibody Production Market Size and Forecast By End User
10.4.1. Brazil Antibody Production Market
10.4.1.1. Increasingly risk for acute respiratory infections.
10.4.2. Mexico Antibody Production Market
10.4.2.1. Prevalence of infectious diseases.
10.4.3. Rest of Latin America Antibody Production Market
11. MEA Antibody Production Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. MEA Antibody Production Market Size and Forecast By Process
11.3. MEA Antibody Production Market Size and Forecast By Type
11.4. MEA Antibody Production Market Size and Forecast By End User
11.5. South Africa Antibody Production Market
11.5.1.1. High incidence of mortality due to infectious diseases
11.6. Rest of MEA Antibody Production Market
12. Companies in the Antibody Production Market
12.1. GE Healthcare
12.1.1. Company Snapshot
12.1.2. Company Overview
12.1.3. Financial Performance (2015-2020)
12.1.3.1. Net Revenue
12.1.3.2. Gross Profit
12.1.3.3. Geographical Revenue, 2020
12.1.4. Product Offerings
12.1.5. Recent Initiatives (2017-2020)
12.2. Thermo Fisher Scientific, Inc.
12.2.1. Company Snapshot
12.2.2. Company Overview
12.2.3. Financial Performance (2015-2020)
12.2.3.1. Net Revenue
12.2.3.2. Gross Profit
12.2.3.3. Geographical Revenue, 2020
12.2.4. Product Offerings
12.2.5. Recent Initiatives (2017-2020)
12.3. 3M
12.3.1. Company Snapshot
12.3.2. Company Overview
12.3.3. Financial Performance (2015-2020)
12.3.3.1. Net Revenue
12.3.3.2. Gross Profit
12.3.3.3. Geographical Revenue, 2020
12.3.4. Product Offerings
12.3.5. Recent Initiatives (2017-2020)
12.4. Abcam PLC
12.4.1. Company Snapshot
12.4.2. Company Overview
12.4.3. Financial Performance (2015-2020)
12.4.3.1. Net Revenue
12.4.3.2. Gross Profit
12.4.3.3. Geographical Revenue, 2020
12.4.4. Product Offerings
12.4.5. Recent Initiatives (2017-2020)
12.5. GeneTex, Inc.
12.5.1. Company Snapshot
12.5.2. Company Overview
12.5.3. Financial Performance (2015-2020)
12.5.3.1. Net Revenue
12.5.3.2. Gross Profit
12.5.3.3. Geographical Revenue, 2020
12.5.4. Product Offerings
12.5.5. Recent Initiatives (2017-2020)
12.6. Sartorius AG
12.6.1. Company Snapshot
12.6.2. Company Overview
12.6.3. Financial Performance (2015-2020)
12.6.3.1. Net Revenue
12.6.3.2. Gross Profit
12.6.3.3. Geographical Revenue, 2020
12.6.4. Product Offerings
12.6.5. Recent Initiatives (2017-2020)
12.7. Merck KGaA
12.7.1. Company Snapshot
12.7.2. Company Overview
12.7.3. Financial Performance (2015-2020)
12.7.3.1. Net Revenue
12.7.3.2. Gross Profit
12.7.3.3. Geographical Revenue, 2020
12.7.4. Product Offerings
12.7.5. Recent Initiatives (2017-2020)
12.8. Pall Corporation
12.8.1. Company Snapshot
12.8.2. Company Overview
12.8.3. Financial Performance (2015-2020)
12.8.3.1. Net Revenue
12.8.3.2. Gross Profit
12.8.3.3. Geographical Revenue, 2020
12.8.4. Product Offerings
12.8.5. Recent Initiatives (2017-2020)
12.9. Sigma-Aldrich Corporation
12.9.1. Company Snapshot
12.9.2. Company Overview
12.9.3. Financial Performance (2015-2020)
12.9.3.1. Net Revenue
12.9.3.2. Gross Profit
12.9.3.3. Geographical Revenue, 2020
12.9.4. Product Offerings
12.9.5. Recent Initiatives (2017-2020)
12.10. Eppendorf AG
12.10.1. Company Snapshot
12.10.2. Company Overview
12.10.3. Financial Performance (2015-2020)
12.10.3.1. Net Revenue
12.10.3.2. Gross Profit
12.10.3.3. Geographical Revenue, 2020
12.10.4. Product Offerings
12.10.5. Recent Initiatives (2017-2020)
12.11. Other Notable Players
13. Conclusion
14. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Antibody Production Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Antibody Production Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Antibody Production Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Antibody Production Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Antibody Production Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Antibody Production Market Drivers & Restraints 2021
Table 7. Antibody Production Submarket Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Antibody Production Submarket Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Antibody Production Submarket Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Antibody Production Submarket Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Antibody Production Submarket Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Upstream Processing Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Upstream Processing Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Upstream Processing Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Upstream Processing Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Upstream Processing Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Downstream Processing Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Downstream Processing Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Downstream Processing Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Downstream Processing Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Downstream Processing Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Filtration Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Filtration Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Filtration Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Filtration Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Filtration Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Antibody Production Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 28. Antibody Production Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Antibody Production Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Antibody Production Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Antibody Production Submarket Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Monoclonal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Monoclonal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Monoclonal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Monoclonal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Monoclonal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Polyclonal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Polyclonal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Polyclonal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Polyclonal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Polyclonal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Antibody Production Market Forecast by End User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Antibody Production Market Forecast by End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Antibody Production Market Forecast by End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Antibody Production Market Forecast by End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Antibody Production Market Forecast by End User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Pharmaceutical & Biotechnology Companies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Pharmaceutical & Biotechnology Companies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Pharmaceutical & Biotechnology Companies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Pharmaceutical & Biotechnology Companies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Pharmaceutical & Biotechnology Companies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Diagnostic Laboratories Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table53. Diagnostic Laboratories Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Diagnostic Laboratories Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Diagnostic Laboratories Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Diagnostic Laboratories Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Regional Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 58. Regional Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Regional Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Regional Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Regional Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 62. North America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 63. North America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 64. North America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 65. North America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 66. North America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 67. North America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 68. North America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 69. North America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 70. North America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 71. North America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 72. North America Antibody Production Market Forecast By End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 73. North America Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 74. North America Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 75. North America Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table76. North America Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 77. North America Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 78. North America Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 79. North America Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 80. North America Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 81. North America Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 82. US Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 83. US Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 84. US Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 85. US Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 86. US Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Canada Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 88. Canada Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Canada Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Canada Antibody Production Market Forecast 2021-2031 (US$M, AGR % CAGR %) (COVID - Scenario W)
Table 91. Canada Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Europe Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 93. Europe Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Europe Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Europe Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Europe Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Europe Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 98. Europe Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Europe Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Europe Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Europe Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Europe Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 103. Europe Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Europe Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Europe Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Europe Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Europe Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 108. Europe Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Europe Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Europe Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Europe Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 112. UK Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 113. UK Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 114. UK Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 115. UK Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 116. UK Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Germany Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 118. Germany Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Germany Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Germany Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Germany Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 122. France Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 123. France Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 124. France Antibody Production Market Forecast 2021-2031 (US$M, AGR % CAGR %) (COVID - Scenario U)
Table 125. France Antibody Production Market Forecast 2021-2031 (US$M, AGR % CAGR %), (COVID - Scenario W)
Table 126. France Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Rest of Europe Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 128. Rest of Europe Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Rest of Europe Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Rest of Europe Antibody Production Market Forecast 2021-2031 (US$M, AGR%, CAGR %) (COVID - Scenario W)
Table 131. Rest of Europe Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Asia Pacific Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 133. Asia Pacific Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Asia Pacific Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Asia Pacific Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Asia Pacific Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Asia Pacific Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 138. Asia Pacific Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Asia Pacific Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Asia Pacific Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Asia Pacific Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 142. Asia Pacific Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 143. Asia Pacific Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 144. Asia Pacific Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 145. Asia Pacific Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 146. Asia Pacific Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L
Table 147. Asia Pacific Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 148. Asia Pacific Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Asia Pacific Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Asia Pacific Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Asia Pacific Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 152. China Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153. China Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154. China Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 155. China Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 156. China Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157. India Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158. India Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159. India Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. India Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161. India Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Japan Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. Japan Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Japan Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Japan Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Japan Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167. RoAPAC Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168. RoAPAC Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. RoAPAC Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170. RoAPAC Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. RoAPAC Antibody Production Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Middle East Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173. Middle East Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. Middle East Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175 Middle East Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. Middle East Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177. Middle East Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. Middle East Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. Middle East Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. Middle East Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. Middle East Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182 Middle East Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183 Middle East Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. Middle East Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185. Middle East Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. Middle East Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. Latin America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. Latin America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. Latin America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190. Latin America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table191. Latin America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192. Latin America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table193. Latin America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. Latin America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. Latin America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. Latin America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. Latin America Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198. Latin America Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199 Latin America Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. Latin America Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. Latin America Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202 Leading 10 Antibody Production Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 203. GE Healthcare Profile 2021 (CEO, HQ, Founded, Website)
Table 253. GE Healthcare Antibody Production Selected Recent Contracts 2021 (Date, Programme Type, Details)
Table 204. GE Healthcare Antibody Production Product Offering (Segment, Product Offerings)
Table 205. Thermo Fisher Scientific, Inc. Profile 2021 (CEO, HQ, Founded, Website)
Table 206. Thermo Fisher Scientific, Inc. Antibody Production Product Offering (Segment, Product Offerings)
Table 207. 3M Profile 2021 (CEO, HQ, Founded, Website)
Table 208. 3M Antibody Production Selected Recent Contracts 2017-2020 (Date, Programme Type, Details)
Table 209. 3M Antibody Production Product Offering (Segment, Product Offerings)
Table 210. Abcam PLC Profile 2021 (CEO, HQ, Founded, Website)
Table 211. Abcam PLC Selected Recent Contracts 2015-2021 (Date, Programme Type, Details)
Table 212. Abcam PLC Antibody Production Parasiticides Product Offering (Segment, Product Offerings)
Table 213. GeneTex, Inc. Profile 2021 (CEO, HQ, Founded, Website)
Table 214. GeneTex, Inc. Antibody Production Product Offering (Segment, Product Offerings)
Table 215. Sartorius AG Profile 2021 (CEO, HQ, Founded, Website)
Table 216. Sartorius AG Antibody Production Selected Recent Contracts 2015-2021 (Date, Programme Type, Details)
Table 217 Sartorius AG Antibody Production Product Offering (Segment, Product Offerings)
Table 218. Merck KGaA Profile 2021 (CEO, HQ, Founded, Website)
Table 219. Merck KGaA Antibody Production Product Offering (Segment, Product Offerings)
Table 220. Pall Corporation, Profile 2021 (CEO, HQ, Founded, Website)
Table 221. Pall Corporation, Antibody Production Product Offering (Segment, Product Offerings)
Table 222. Sigma-Aldrich Corporation Profile 2021 (CEO, HQ, Founded, Website)
Table 223. Sigma-Aldrich Corporation Antibody Production Product Offering (Segment, Product Offerings)
Table 224. Eppendorf AG Profile 2021 (CEO, Total Company Sales US$M, HQ, Founded, No. of Employees, Ticker, Website)
Table 225. Eppendorf AG Total Company Sales 2015-2021 (US$M, AGR %)
Table 226. Eppendorf AG Product Offering (Segment, Product Offerings)
Table 227. Other Companies Involved in the Antibody Production Market (Company, Location)
LIST OF FIGURES
Figure 1. Antibody Production Market Type Overview
Figure 2. Antibody Production Market By Process Overview
Figure 3. Antibody Production Market By Type Overview
Figure 4. Antibody Production Market End User Overview
Figure 5. Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 6. Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 7. Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 8. Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 9. Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 10. Antibody Production Submarket Forecast By Process 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 11. Antibody Production Submarket Forecast By Process 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 12. Antibody Production Submarket Forecast By Process 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 13. Antibody Production Submarket Forecast By Process 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 14. Antibody Production Submarket Forecast By Process 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 15. Antibody Production Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 16. Antibody Production Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 17. Antibody Production Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 18. Antibody Production Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 19. Antibody Production Submarket Forecast By Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 20. Antibody Production Submarket Forecast by End User 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 21. Antibody Production Submarket Forecast by End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 22. Antibody Production Submarket Forecast by End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 23. Antibody Production Submarket Forecast by End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 24. Antibody Production Submarket Forecast by End User 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 25. Regional Antibody Production Market Forecast 2021-2031 (Sales US$M, Global AGR %) (Before COVID)
Figure 26. Regional Antibody Production Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario V)
Figure27. Regional Antibody Production Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario U)
Figure 28. Regional Antibody Production Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario W)
Figure 29. Regional Antibody Production Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario L)
Figure 30. North America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %) (Before COVID)
Figure 31. North America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 32. North America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 33. North America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 34. North America Antibody Production Market Forecast By Process 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 35. North America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %) (Before COVID)
Figure 36. North America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 37. North America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 38. North America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 39. North America Antibody Production Market Forecast By Type 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 40. North America Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %) (Before COVID)
Figure 41. North America Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 42. North America Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 43. North America Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 44. North America Antibody Production Market Forecast by End User 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 45. North America Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 46. North America Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 47. North America Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 48. North America Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 49. North America Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 50. US Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 51. US Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 52. US Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 53. US Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 54. US Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 55. Canada Antibody Production Market Forecast 2021-2031 (US$M, AGR %)
Figure 56. Canada Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 57. Canada Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 58. Canada Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 59. Canada Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 60. Europe Antibody Production Market Forecast By Process 2021-2031 (US$M)
Figure 61. Europe Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario V)
Figure 62. Europe Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario U)
Figure 63. Europe Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario W)
Figure 64. Europe Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario L)
Figure 65. Europe Antibody Production Market Forecast By Type 2021-2031 (US$M) (Before COVID)
Figure 66. Europe Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 67. Europe Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 68. Europe Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 69. Europe Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 70. Europe Antibody Production Market Forecast by End User 2021-2031 (US$M) (Before COVID)
Figure 71. Europe Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 72. Europe Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 73. Europe Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 74. Europe Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 75. Europe Antibody Production Market Forecast by Country 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 76. Europe Antibody Production Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 77. Europe Antibody Production Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 78. Europe Antibody Production Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 79. Europe Antibody Production Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 80. UK Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 81. UK Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 82. UK Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID – Scenario U)
Figure 83. UK Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 84. UK Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 85. Germany Antibody Production Market Forecast 2021-2031 (US$M, AGR %)
Figure 86. Germany Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 87. Germany Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 88. Germany Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 89. Germany Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 90. France Antibody Production Market Forecast 2021-2031 (US$M, AGR %)
Figure 91. France Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 92. France Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 93. France Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 94. France Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 95. Rest of Europe Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 96. Rest of Europe Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 97. Rest of Europe Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 98. Rest of Europe Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 99. Rest of Europe Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 100 Asia-Pacific Antibody Production Market Forecast By Process 2021-2031 (US$M) (Before COVID)
Figure 101. Asia-Pacific Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario V)
Figure 102. Asia-Pacific Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario U)
Figure 103. Asia-Pacific Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario W)
Figure 104. Asia-Pacific Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario L)
Figure 105. Asia-Pacific Antibody Production Market Forecast By Type 2021-2031 (US$M)
Figure 106. Asia-Pacific Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 107. Asia-Pacific Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 108. Asia-Pacific Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 109. Asia-Pacific Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 110. Asia-Pacific Antibody Production Market Forecast By Type 2021-2031 (US$M)
Figure 111. Asia-Pacific Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 112. Asia-Pacific Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 113. Asia-Pacific Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 114. Asia-Pacific Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 115. Asia-Pacific Antibody Production Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 116. Asia-Pacific Antibody Production Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 117. Asia-Pacific Antibody Production Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 118. Asia-Pacific Antibody Production Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 119. Asia-Pacific Antibody Production Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 120. China Antibody Production Market Forecast 2021-2031 (US$M, AGR %)
Figure 121. China Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 122. China Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 123 China Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 124. China Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 125. India Antibody Production Market Forecast 2021-2031 (US$M, AGR %)
Figure 126. India Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 127. India Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 128. India Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 129. India Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 130. Japan Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 131. Japan Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 132. Japan Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 133. Japan Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 134. Japan Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 135. Rest of APAC Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 136. Rest of APAC Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 137 Rest of APAC Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 138. Rest of APAC Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 139. Rest of APAC Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 140. Middle East Antibody Production Market Forecast By Process 2021-2031 (US$M)
Figure 141. Middle East Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario V)
Figure 142. Middle East Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario U)
Figure 143. Middle East Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario W)
Figure 144. Middle East Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario L)
Figure 145. Middle East Antibody Production Market Forecast By Type 2021-2031 (US$M)
Figure 146. Middle East Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 147 Middle East Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 148. Middle East Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 149. Middle East Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 150. Middle East Antibody Production Market Forecast by End User 2021-2031 (US$M)
Figure 151. Middle East Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 152. Middle East Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 153. Middle East Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 154. Middle East Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 155. Rest of Middle East Antibody Production Market Forecast 2021-2031 (US$M, AGR %)
Figure 156. Rest of Middle East Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 157. Rest of Middle East Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 158. Rest of Middle East Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 159. Rest of Middle East Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 160. Latin America Antibody Production Market Forecast By Process 2021-2031 (US$M)
Figure 161. Latin America Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario V)
Figure 162. Latin America Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario U)
Figure 163. Latin America Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario W)
Figure 164. Latin America Antibody Production Market Forecast By Process 2021-2031 (US$M) (COVID - Scenario L)
Figure 165. Latin America Antibody Production Market Forecast By Type 2021-2031 (US$M)
Figure 166. Latin America Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 167. Latin America Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 168. Latin America Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 169. Latin America Antibody Production Market Forecast By Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 170. Latin America Antibody Production Market Forecast by End User 2021-2031 (US$M)
Figure 171. Latin America Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario V)
Figure 172. Latin America Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario U)
Figure 173. Latin America Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario W)
Figure 174. Latin America Antibody Production Market Forecast by End User 2021-2031 (US$M) (COVID - Scenario L)
Figure 175. Rest of Latin America Antibody Production Market Forecast 2021-2031 (US$M, AGR %)
Figure 176. Rest of Latin America Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 177. Rest of Latin America Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 178. Rest of Latin America Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 179. Rest of Latin America Antibody Production Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 180. Porter’s Five Force Analysis
Companies Mentioned
1. GE Healthcare
2. Thermo Fisher Scientific, Inc.
3. 3M
4. Abcam PLC
5. GeneTex, Inc.
6. Sartorius AG
7. Merck KGaA
8. Pall Corporation
9. Sigma-Aldrich Corporation
10. Eppendorf AG
11. Cellab GmbH
12. Pfizer
13. INTEGRA Biosciences AG
14. FiberCell Systems Inc.
15. Eli Lilly and Company
16. Abcam PLC
17. Alexion
18. F. Hoffmann-La Roche AG
19. Janssen Biologics
20. AbbVie
21. Novartis AG
22. Gilead Sciences
23. AstraZeneca
24. Glenmark Pharmaceuticals Ltd.
25. CytoDyn Inc.
26. Regeneron Pharmaceuticals, Inc.
27. Immunic Inc.
28. Molecular Partners AG
29. Biophytis SA
30. HiFiBiO Inc.
31. Atea Pharmaceuticals, Inc.
32. UNION therapeutics A/S
33. Appili Therapeutics Inc.
34. GlaxoSmithKline Biologicals
35. Corvus Pharmaceuticals Inc.
36. Sorrento Therapeutics, Inc.
37. Eiger BioPharmaceuticals, Inc.
38. Amgen Inc.
39. Vir Biotechnology
40. Humanigen Inc.
41. Innovation pharmaceuticals Inc.
42. Mateon Therapeutics
43. Dr. Reddy’s Laboratories Ltd.
44. RedHill Biopharma Ltd
45. Harbour BioMed
46. Mesoblast Limited
47. Organicell Regenerative Medicine, Inc.
48. Abeome Corporation
49. Laurent Pharmaceuticals Inc
50. Capricor Therapeutic
Companies Profiled in the Report
1. Pfizer Inc.
2. Thermo Fisher Scientific Inc.
3. Astellas Pharma, Inc
4. F. Hoffmann-La Roche AG
5. Novartis AG
6. Bristol-Myers Squibb Co.
7. Bayer HealthCare AG
8. Merck KGaA,
9. Abbott Laboratories
10. Takeda Pharmaceutical Company Ltd.
11. Daiichi Sankyo Company, Ltd.
12. GlaxoSmithKline Plc
13. Eli Lilly and Co.
14. Kyorin Pharmaceutical Co., Ltd.
List of Companies Mentioned in the Report:
1. GE Healthcare
2. Thermo Fisher Scientific, Inc.
3. 3M
4. Abcam PLC
5. GeneTex, Inc.
6. Sartorius AG
7. Merck KGaA
8. Pall Corporation
9. Sigma-Aldrich Corporation
10. Eppendorf AG
11. Cellab GmbH
12. Pfizer
13. INTEGRA Biosciences AG
14. FiberCell Systems Inc.
15. Eli Lilly and Company
16. Abcam PLC
17. Alexion
18. F. Hoffmann-La Roche AG
19. Janssen Biologics
20. AbbVie
21. Novartis AG
22. Gilead Sciences
23. AstraZenca
24. Glenmark Pharmaceuticals Ltd.
25. CytoDyn Inc.
26. Regeneron Pharmaceuticals, Inc.
27. Immunic Inc.
28. Molecular Partners AG
29. Biophytis SA
30. HiFiBiO Inc.
31. Atea Pharmaceuticals, Inc.
32. UNION therapeutics A/S
33. Appili Therapeutics Inc.
34. GlaxoSmithKline Biologicals
35. Corvus Pharmaceuticals Inc.
36. Sorrento Therapeutics, Inc.
37. Eiger BioPharmaceuticals, Inc.
38. Amgen Inc.
39. Vir Biotechnology
40. Humanigen Inc.
41. Innovation pharmaceuticals Inc.
42. Mateon Therapeutics
43. Dr. Reddy’s Laboratories Ltd.
44. RedHill Biopharma Ltd
45. Harbour BioMed
46. Mesoblast Limited
47. Organicell Regenerative Medicine, Inc.
48. Abeome Corporation
49. Laurent Pharmaceuticals Inc
50. Capricor Therapeutics
List of Organizations Mentioned in the Report
1. World Health Organization
2. The Anti body Registry
3. The European Medicines Agency (EMA)
4. European Rapid Alert System for Food and Feed (RASFF)
5. US Food & Drug Administration
6. US National Library of Medicine
7. Mayo Clinic
8. National Institutes of Health
9. National Association for Biomedical Research
10. U.S. Center for Disease Control and Prevention (CDC)
11. National Foundation for Infectious Diseases.
12. The Pew Foundation’s Antibiotic Resistance Project’s
13. Hazard Analysis Critical Control Point (HACCP)
14. The Reportable Food Registry (RFR)
15. Clinical Infectious Diseases
16. Government of Canada
17. The European Free Trade Association Surveillance Authority (ESA)
18. Center for Diseases Dynamics, Economics & Policy (CDDEP)
19. National Reference Laboratory of Veterinary Drug Residues
20. The Federation of Veterinarians of Europe
21. The Global Health Security Agenda (GHSA)
1. Pfizer Inc.
2. Thermo Fisher Scientific Inc.
3. Astellas Pharma, Inc
4. F. Hoffmann-La Roche AG
5. Novartis AG
6. Bristol-Myers Squibb Co.
7. Bayer HealthCare AG
8. Merck KGaA,
9. Abbott Laboratories
10. Takeda Pharmaceutical Company Ltd.
11. Daiichi Sankyo Company, Ltd.
12. GlaxoSmithKline Plc
13. Eli Lilly and Co.
14. Kyorin Pharmaceutical Co., Ltd.
List of Companies Mentioned in the Report:
1. GE Healthcare
2. Thermo Fisher Scientific, Inc.
3. 3M
4. Abcam PLC
5. GeneTex, Inc.
6. Sartorius AG
7. Merck KGaA
8. Pall Corporation
9. Sigma-Aldrich Corporation
10. Eppendorf AG
11. Cellab GmbH
12. Pfizer
13. INTEGRA Biosciences AG
14. FiberCell Systems Inc.
15. Eli Lilly and Company
16. Abcam PLC
17. Alexion
18. F. Hoffmann-La Roche AG
19. Janssen Biologics
20. AbbVie
21. Novartis AG
22. Gilead Sciences
23. AstraZenca
24. Glenmark Pharmaceuticals Ltd.
25. CytoDyn Inc.
26. Regeneron Pharmaceuticals, Inc.
27. Immunic Inc.
28. Molecular Partners AG
29. Biophytis SA
30. HiFiBiO Inc.
31. Atea Pharmaceuticals, Inc.
32. UNION therapeutics A/S
33. Appili Therapeutics Inc.
34. GlaxoSmithKline Biologicals
35. Corvus Pharmaceuticals Inc.
36. Sorrento Therapeutics, Inc.
37. Eiger BioPharmaceuticals, Inc.
38. Amgen Inc.
39. Vir Biotechnology
40. Humanigen Inc.
41. Innovation pharmaceuticals Inc.
42. Mateon Therapeutics
43. Dr. Reddy’s Laboratories Ltd.
44. RedHill Biopharma Ltd
45. Harbour BioMed
46. Mesoblast Limited
47. Organicell Regenerative Medicine, Inc.
48. Abeome Corporation
49. Laurent Pharmaceuticals Inc
50. Capricor Therapeutics
List of Organizations Mentioned in the Report
1. World Health Organization
2. The Anti body Registry
3. The European Medicines Agency (EMA)
4. European Rapid Alert System for Food and Feed (RASFF)
5. US Food & Drug Administration
6. US National Library of Medicine
7. Mayo Clinic
8. National Institutes of Health
9. National Association for Biomedical Research
10. U.S. Center for Disease Control and Prevention (CDC)
11. National Foundation for Infectious Diseases.
12. The Pew Foundation’s Antibiotic Resistance Project’s
13. Hazard Analysis Critical Control Point (HACCP)
14. The Reportable Food Registry (RFR)
15. Clinical Infectious Diseases
16. Government of Canada
17. The European Free Trade Association Surveillance Authority (ESA)
18. Center for Diseases Dynamics, Economics & Policy (CDDEP)
19. National Reference Laboratory of Veterinary Drug Residues
20. The Federation of Veterinarians of Europe
21. The Global Health Security Agenda (GHSA)
Download sample pages
Complete the form below to download your free sample pages for Antibody Production Market Report to 2031Related reports
Biosimilar Monoclonal Antibodies Market Report 2022-2032
The global biosimilar monoclonal antibodies market was valued at US$4,087 million in 2021 and is projected to grow at a...Full DetailsPublished: 25 July 2022Antinuclear Antibody Test Market Report to 2031
Where is the Global Antinuclear Antibody Test market heading? If you are involved in this sector you must read this...Full DetailsPublished: 01 January 1970Microcarrier Market Report 2021-2031
In the pharmaceutical industry, cell culture is progressively becoming a noticeable part of vaccine production. Previously, vaccines were manufactured by...
Full DetailsPublished: 01 January 1970Single-Use Bioreactors Market Report 2021-2031
Strong product portfolio in the market is one of the major factors accelerating the growth of the market as availability...Full DetailsPublished: 10 May 2021Bioprocess Validation Market Report 2021-2031
High demand for outsourcing of bioprocess validation services, stringent safety and quality regulations governing products certifications and testing beyond the...
Full DetailsPublished: 01 January 1970Antibody Drug Conjugates Market Report 2022-2032
The Antibody Drug Conjugates market is projected to grow at a CAGR of 15.1% by 2032....Full DetailsPublished: 28 November 2022
Download sample pages
Complete the form below to download your free sample pages for Antibody Production Market Report to 2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes 3D Cell Culture and 3D Bioprinting Market Report 2023-2033
The global 3D Cell Culture and 3D Bioprinting market is valued at US$2,277.2 million in 2023 and is projected to grow at a CAGR of 17.8% during the forecast period 2023-2033.
03 October 2023
Visiongain Publishes Bioreactors Market Report 2023-2033
The global Bioreactors market was estimated to be valued at US$9,977.0 million in 2023 and is expected to register a CAGR of 12.2% from 2023 to 2033.
29 September 2023
Visiongain Publishes 3D Printing for Healthcare Market Report 2023-2033
The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.
27 September 2023
Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033
The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.
25 September 2023
